FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser: Davidson Kempner Capital Management LP
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):
        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
 
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Tate & Lyle plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  
(e)   Date position held/dealing undertaken:
        For an opening position disclosure, state the latest practicable date prior to the disclosure
30/09/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?
        If it is a cash offer or possible cash offer, state “N/A”
 

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security: 29 1/6p ordinary
(ISIN-GB00BP92CJ43)
  Interests Short positions
Number % Number %
(1)   Relevant securities owned and/or controlled:        
(2)   Cash-settled derivatives: 14,080,629 3.16%    
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:        
        TOTAL: 14,080,629 3.16%    

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:  
Details, including nature of the rights concerned and relevant percentages:  

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchase/sale Number of securities Price per unit

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
29 1/6p ordinary CFD Increasing a long position 1,385,852 GBP 5.5850

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
 

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i)   the voting rights of any relevant securities under any option; or
(ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
 

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO

Date of disclosure: 01/10/2026
Contact name: Alex McMillan
Telephone number: 646 282 5805

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

SINGAPORE, Oct. 01, 2026 (GLOBE NEWSWIRE) — Phaos Technology Holdings (Cayman) Limited, (NYSE American: POAS), (“Phaos” or “the Company”), an advanced microscopy technology company headquartered in Singapore, today announced that it has entered into a securities purchase agreement (the “Purchase Agreement”), dated as of September 28, 2026, with High West Partners LLC, a California limited liability company (the “Investor”). Under the Purchase Agreement, the Company has the right, but not the obligation, to sell to the Investor from time to time up to US$10,000,000 of its Class A ordinary shares, at prevailing market prices and subject to the terms, conditions and limitations set out in the Purchase Agreement and the applicable NYSE listing rules. The Company’s right to sell Ordinary Shares to the Investor begins on the date on which the conditions to the Company’s right to sell, and the Investor’s obligation to purchase, Ordinary Shares under the Purchase Agreement are satisfied (the “Commencement Date”), and expires on the 36-month anniversary of the Commencement Date. The Company has also agreed to issue a number of Class A ordinary shares to the Investor as a commitment fee, which will be fully earned as of the Commencement Date and issued upon the delivery of the first purchase notice.

About Phaos Technology Holdings (Cayman) Limited
Phaos Technology Holdings (Cayman) Limited is an advanced microscopy technology company. Our commitment to innovation and excellence drives us to deliver state-of-the-art microscopy products and software solutions, powered by artificial intelligence, for diverse sectors including manufacturing, biomedical, and research. Experience the difference with Phaos Technology – where innovation meets sophistication, shaping the future of optical technology. For more information, please visit www.phaostech.com.

Forward Looking Statements
This news release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that indicate future events or trends or are not statements of historical matters. These statements are based on our management’s current expectations and beliefs, as well as a number of assumptions concerning future events.
Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside of our control and all of which could cause actual results to differ materially from the results discussed in the forward-looking statements. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Factors that could cause actual results to differ materially from those expressed or implied in forward-looking statements can be found in our reports filed with the United States Securities and Exchange Commission, which are available, free of charge, on the SEC’s website at www.sec.gov.

For more information please contact:

Company Contact:
Phaos Technology Holdings (Cayman) Limited
(65) 6250 3877
ir@phaostech.com

FORT WORTH, Texas, Oct. 01, 2026 (GLOBE NEWSWIRE) — American Airlines Group (NASDAQ: AAL) will webcast a live audio feed of its third-quarter 2026 financial results conference call Oct. 22 at 7:30 a.m. CT.

The webcast will be available on a listen-only basis at aa.com/investorrelations. An archive of the call will be available on the website.

About American Airlines Group (NASDAQ: AAL)
American Airlines is a premium global airline connecting more of the U.S. to the world. With roots tracing back to an air mail carrier in the Midwestern United States in 1926, American now operates more than 6,000 daily flights to more than 350 destinations in more than 60 countries and serves more than 200 million customers annually. Powered by a proud and talented team of 130,000 aviation professionals, American’s team lives out the airline’s purpose of caring for people on life’s journey every day.

The world’s largest airline proudly celebrates its centennial year in 2026, reaching a milestone that reflects a century of innovation and the Forever ForwardSM spirit that changed the industry and the world. American introduced the first scheduled air cargo service, the first airport lounge and the first airline loyalty program and continues to reinvent the customer experience today. The airline is also a founding member of the oneworld alliance, whose members serve more than 900 destinations around the globe.

Get the latest about American at news.aa.com and @AmericanAir.

Corporate Communications
mediarelations@aa.com 
Investor Relations
investor.relations@aa.com

Join Unity Bank to support families in need

Unity Bank’s Charity Car Show

Sunday, October 4, 2026, from 10:00 am to 2:00 pm
Sunday, October 4, 2026, from 10:00 am to 2:00 pm

Unity Bank’s Charity Car Show

Sunday, October 4, 2026, from 10:00 am to 2:00 pm
Sunday, October 4, 2026, from 10:00 am to 2:00 pm

CLINTON, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) — Unity Bank is inviting classic car owners, local businesses, and community members to participate in the 20th Anniversary Unity Bank Charity Car Show, to be held at the bank’s corporate headquarters, located at 64 Old Highway 22 in Clinton, on Sunday, October 4, 2026, from 10:00 am to 2:00 pm.

The event will benefit Family Promise of Warren County and Family Promise of Hunterdon County, with all proceeds helping the organizations continue their mission of assisting families experiencing or at risk of homelessness. Unity Bank employees also volunteer their time to organize and support the annual fundraiser.

“For twenty years, our Charity Car Show has brought together car enthusiasts, local businesses, employees, and community members to make a meaningful difference for families in need,” said James A. Hughes, CEO of Unity Bank. “What started as a local car show has grown into a signature community event that reflects Unity Bank’s commitment to giving back. We are proud to celebrate this 20-year milestone while supporting the important work of Family Promise and the families they serve.”

The family-friendly event will feature an impressive collection of classic, custom, and specialty vehicles, along with music, food vendors, contests, a 50/50 raffle, the popular Blizzard of Dollars money machine, free face painting and balloon animals for children, and a variety of prizes and activities throughout the day. Doctor D. Entertainment will serve as the event emcee.

Admission is free for spectators, and community members are encouraged to attend with family and friends to support the charitable cause.

Car owners may register their vehicles online at www.unitybank.com/carshow. Vehicle registration is $20 per car, with registration opening at 8:30 am on the day of the event. Participants will have the opportunity to compete for trophies and prizes in various vehicle categories.

Over the past two decades, Unity Bank’s Charity Car Show has raised thousands of dollars to support local nonprofit organizations and has become a highly anticipated annual tradition throughout the region. Organizers expect another strong turnout as the community comes together to celebrate the event’s 20th anniversary and support two organizations making a positive impact on local families.

Family Promise of Hunterdon County and Family Promise of Warren County are dedicated to helping families overcome and prevent homelessness through a comprehensive network of services, including emergency shelter, meals, case management, counseling, housing assistance, and other supportive programs designed to promote long-term stability and self-sufficiency.

For additional event information or to register a vehicle, visit: www.unitybank.com/carshow

About Unity Bancorp, Inc.

Unity Bancorp, Inc. (NASDAQ: UNTY) is the parent company of Unity Bank, a financial services organization based in Clinton, New Jersey. Unity Bank operates 22 branches across New Jersey and the Lehigh Valley, Pennsylvania, offering community-focused commercial banking services, including deposit accounts, loans, and digital services. For details, visit unitybank.com or call 800-618-BANK (800-618-2265). Unity Bank is a member of the Federal Deposit Insurance Corporation (FDIC). To learn about FDIC insurance, visit FDIC.gov.

Contact:
Crystal Rose
Chief Marketing Officer
(908) 713-4310
Crystal.Rose@unitybank.com

Photos accompanying this announcement are available at 

https://www.globenewswire.com/NewsRoom/AttachmentNg/49dbba1e-95f6-4e91-afe3-57392c405c2

https://www.globenewswire.com/NewsRoom/AttachmentNg/a271d20f-43df-46de-a339-83b8cb238b3e

New release extends trusted enterprise AI across delivery, retrieval and content ingestion, enabling organizations to scale AI experiences without rebuilding existing deployments

BURLINGTON, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) — Progress Software (Nasdaq: PRGS), an AI infrastructure software leader, today announced new capabilities within Progress® Agentic RAG, an agentic retrieval-augmented generation (RAG) platform for AI agents and LLMs that connects enterprise knowledge to AI-powered experiences through a shared Agentic Knowledge Layer. The release includes a native Microsoft Teams application, a new Smart Agent for autonomous multistep retrieval and a WordPress plugin that improves content ingestion, fidelity and governance.

As organizations move AI agents beyond simple chat into systems that can plan, retrieve information and act across the business, complexity grows quickly. Engineering teams often find themselves building and maintaining custom orchestration logic for every system an agent must access. At the same time, agents that rely only on pre-indexed content can return incomplete or outdated answers, may require employees to continue switching between applications to find the information they need, limit adoption and reduce the value of AI investments.

The latest Progress Agentic RAG platform release gives organizations two complementary ways to put their knowledge behind AI agents. Content can be ingested in advance through a governed Knowledge Box and kept continuously synchronized for fast, trusted retrieval. In addition, native Model Context Protocol (MCP) support in the platform’s Smart Agent enables agents to access live business systems and web sources at the moment a question is asked, without duplicating data or requiring custom integrations for every system. Together, these capabilities help organizations bring AI into the tools employees use every day, deliver answers that span multiple systems and keep information current, all while preserving governance and avoiding costly rebuilds.

“The next phase of enterprise AI will not be defined by systems that simply retrieve information. It will be defined by AI that can navigate complex questions, work across organizational knowledge and deliver answers where people already work,” said John Ainsworth, EVP and General Manager, Application and Data Platform, Progress Software. “The latest release of Progress Agentic RAG allows organizations to more easily address increasingly complex questions by building on its strong foundation of delivering trusted AI experiences that drive successful business outcomes.”

New capabilities include:

  • Native Microsoft Teams Application
    Available through the Microsoft Store, the Progress Agentic RAG platform Teams app brings trusted, source-cited AI experiences directly into Teams chats and channels. By bringing AI into a collaboration platform employees already use every day, organizations can accelerate adoption and give users access to enterprise knowledge, while maintaining existing permissions and governance controls without leaving their existing workflows.
  • Smart Agent for Multistep Retrieval
    The new Smart Agent plans queries, creates sub-questions, retrieves information across a Knowledge Box, MCP-connected applications and web sources and evaluates results until sufficient information has been gathered. This enables organizations to answer more complex cross-system questions while reducing the need for custom orchestration and source-routing logic.
  • WordPress Plugin for Richer Content Ingestion
    The native WordPress plugin gives administrators greater control over how WordPress content is indexed and refreshed within Progress Agentic RAG. By preserving content structure, metadata and taxonomy information, it improves retrieval quality, helps keep AI experiences aligned with current content and strengthens governance of enterprise knowledge.

Existing Progress Agentic RAG customers inherit all three capabilities using the same indexed content, access controls and quality framework already in place, with no reindexing, pipeline rebuilds or architectural changes required.

The latest release of Progress Agentic RAG is now available. For more information, visit https://www.progress.com/agentic-rag.

About Progress Software

Progress Software (Nasdaq: PRGS) provides the context and control organizations need to reliably extract value from AI—context drawn from an organization’s data, content and workflows, and control over the security, governance and cost of their AI initiatives. Learn how hundreds of thousands of businesses, powering the work of tens of millions of professionals worldwide, realize value from trusted, enterprise-ready AI at www.progress.com.

Progress and certain product names used herein are trademarks or registered trademarks of Progress Software Corporation and/or one of its subsidiaries or affiliates in the U.S. and/or other countries. See trademarks for appropriate markings. All rights in any other trademarks contained herein are reserved by their respective owners and their inclusion does not imply an endorsement, affiliation or sponsorship as between Progress and the respective owners.

Press Contact:
Kim Baker
Progress Software
+1-800-477-6473
pr@progress.com

On August 31, 2026, Aktsiaselts Infortar issued a stock exchange announcement, disclosing the signing of a purchase agreement with Best Print OÜ under which Aktsiaselts Infortar will sell its 100% shareholding in Tallinna Raamatutrükikoja OÜ and its 100% subsidiary Vaba Maa AS, as well as its 60% shareholding in its subsidiary CardPlus VM OÜ (together, the TRT group).

The Competition Authority has granted a merger permit to complete the transaction and today following fulfilment of the remaining conditions, Aktsiaselts Infortar sold its shareholding in TRT group.

The contemplated transaction is not a transaction between related parties. The members of the Supervisory Board and the Management Board of Aktsiaselts Infortar have no personal interest in the transaction in any other way.

Infortar operates in seven countries, the company’s main fields of activity are maritime transport, energy and real estate. Infortar owns a 68.83% shareholding in Tallink Grupp, a 100% share in Elenger Grupp and a versatile and modern real estate portfolio of approx. 141,000 m2. In addition to the three main areas of activity, Infortar also operates in construction and mineral resources, agriculture, and other areas. A total of 107 companies belong to the Infortar group, including 3 associates and 2 subsidiaries of associates. Infortar employs 6890 people.

Additional information:

Kadri Laanvee
Investor Relations Manager
Phone: +372 5156662
e-mail: kadri.laanvee@infortar.ee
www.infortar.ee/en/investor

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS

Neuberger Private Equity Partners Announces Change in Registered Office

St Peter Port, Guernsey, 1 October 2026

Neuberger Private Equity Partners Limited (“NBPE” or the “Company”) today announces that with effect from the 1 October 2026, its Registered Office has changed to Ground floor, Mill Court, La Charroterie, St Peter Port, Guernsey, GY1 1EJ.

This is as a result of the change in Registered Office of its Guernsey Administrator, who has also changed its name from Oak Fund Services (Guernsey) Limited to Highvern Fund Services Limited.

For further information, please contact:

NBPE Investor Relations        +44 20 3214 9002
Luke Mason        NBPrivateMarketsIR@nb.com

Highvern Fund Services         +44 1481668732

        NBPEP@oak.group

About Neuberger Private Equity Partners Limited

Neuberger Private Equity Partners Limited (“NBPE”) invests in direct private equity investments alongside market leading private equity firms globally. NB Alternatives Advisers LLC (the “Investment Manager”), an indirect wholly owned subsidiary of Neuberger Berman Group LLC, is responsible for sourcing, execution and management of NBPE. The vast majority of direct investments are made with no management fee / no carried interest payable to third-party GPs, offering greater fee efficiency than other listed private equity companies. NBPE seeks capital appreciation through growth in net asset value over time while paying a bi-annual dividend.

LEI number: 213800UJH93NH8IOFQ77

About Neuberger

Neuberger was founded in 1939 to do one thing: deliver compelling investment results for our clients over the long term. This remains our singular purpose today, driven by a culture rooted in deep fundamental research, the pursuit of investment insight and continuous innovation on behalf of clients, and facilitated by the free exchange of ideas across the organization.

From offices in 39 cities[1] across 26 countries, Neuberger manages a range of equity, fixed income, private equity and hedge fund strategies on behalf of institutions, advisors and individual investors worldwide. With more than 780[1] investment professionals and over 2,900[1] employees in total, Neuberger has built a diverse team of individuals united in their commitment to client outcomes and investment excellence. Our culture has afforded us enviable retention rates among our senior investment staff and we are proud to have been ranked 1st by Pensions & Investments in their 2025 “Best Places to Work in Money Management” survey, where we have placed 1st in four of the last five years and finished in the top two for 12 consecutive years[2].

As a private, independent, employee-owned investment manager, Neuberger is structurally aligned with the long-term interests of our clients. We have no external parent or public shareholders to serve, nor other lines of business to distract us from our core mission. And with our employees and their families invested alongside our clients—plus 100% of employee deferred cash compensation directly linked to team and firm strategies—we are truly in this together.
For more information, please visit our website: www.nb.com/en/global/who-we-are.

Media Contacts:
US: Soogyung Jordan: Soogyung.Jordan@nb.com
EMEA: Fiona Kehily: Fiona.Kehily@nb.com

[1] Firm data reflects the collective data for the various subsidiaries of Neuberger Berman Group LLC as of 30 June 2026.

[2] Among organizations with over 1,000 employees by Pensions & Investments. For additional information on the criteria for the award, please visit https://www.pionline.com/awards/best-places-to-work-in-money-management/pi-best-places-to-work-2025.

This material is issued on a limited basis through various global subsidiaries and affiliates of Neuberger Berman Group LLC. Please visit www.nb.com/disclosure-global-communications to learn about each company and the legal restrictions and restrictions. The name “Neuberger Berman” and logo are registered service marks of Neuberger Berman Group LLC.

© 2026 Neuberger Berman Group LLC. All rights reserved.

Court Overturns $22.7 Million Damages Award

BROOMFIELD, Colo., Oct. 01, 2026 (GLOBE NEWSWIRE) — Gogo Inc. (NASDAQ: GOGO) today issued the following statement regarding the U.S. District Court for the District of Delaware’s ruling on post-trial motions in SmartSky Networks, LLC v. Gogo Business Aviation, LLC and Gogo Inc.:

“We are pleased that the court has overturned the jury’s $22.7 million damages award in its entirety, concluding that SmartSky failed to prove any recoverable damages and denying its requests for enhanced damages, ongoing royalties, and interest. In reaching that decision, the court found that SmartSky’s damages award was untethered to the evidentiary record, relying on assumptions that could not be reconciled with the facts of the case. This ruling represents a significant step in resolving this matter, and we look forward to bringing it to a full and final close so that we can return our sole focus to delivering multi-orbit, multi-band connectivity technology purpose-built for business and military/government mobility aviation customers.”

The court’s September 30, 2026 ruling is subject to appeal.

About Gogo

Gogo has been the trusted connectivity infrastructure partner for military and government operations and business aviation for three decades. Rather than promoting a single network or technology, Gogo Special Missions has a network-neutral approach, helping military and government customers navigate an increasingly complex communications landscape by combining deep market knowledge and global aviation expertise to identify, integrate and support the connectivity solution best suited to each mission and operational requirement.

Providing access to a complete connectivity ecosystem through a single trusted partner, Gogo Special Missions offers onboard hardware, software, air-to-ground and multi-orbit, multi-band satellite connectivity, service plans, and 24/7/365 multilingual customer support. The company’s interoperable solutions securely connect crewed and uncrewed aircraft across the operational theatre, enabling seamless communications in any mission environment. Dedicated to customer success, Gogo Special Missions delivers the flexibility, resilience and choice customers need while ensuring predictable pricing and future-proof technology.

From ISR and command-and-control missions to executive transport, humanitarian operations and emergency response, Gogo delivers secure, reliable, mission-critical connectivity that enables customers to execute every mission with confidence.

Investor Relations Contact
        
Amy Greene        
+1 303-301-3313        
agreene@gogoair.com

Media Relations Contact
Stacey Giglio
+1 321-361-6101
sgiglio@gogoair.com

Significantly Expands H2O America’s Texas Footprint into the High-Growth Houston Region

SAN JOSE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) — H2O America (NASDAQ: HTO) today announced that its regulated Texas water and wastewater utility, The Texas Water Company, Inc. (“TWC”), along with its affiliate Texas Water Operation Services, LLC (“TWOS”), have completed the acquisition of all assets owned by Quadvest.

“This is a significant milestone in our strategy to build a stronger utility portfolio, with Quadvest’s operations projected to deliver double-digit customer growth over the next several years in some of the country’s fastest-growing counties,” said Andrew F. Walters, chair of the H2O America board of directors and chief executive officer of H2O America. “Texas is an increasingly meaningful driver of H2O America’s long-term ability to provide sustainable value for all of our customers, communities and shareholders, and the addition of Quadvest’s people and resources to our TWC team reinforces our confidence in the opportunities we see to serve customers across the great state of Texas.”

The acquisition more than doubles H2O America’s water and wastewater connections in Texas, providing greater scale to support continued investment in critical infrastructure and operational excellence for Hill Country and Houston-area communities. With the addition of Quadvest’s operations and anticipated buildout of its development pipeline, H2O America expects Texas customers to represent 26% of the company’s overall customer base by 2029 – a transformative increase from the 8% that Texas customers represent prior to Oct. 1. For H2O America, a more geographically and regulatorily diverse utility portfolio also helps reduce exposure to weather, climate and jurisdiction-specific risks across the company’s portfolio.

Quadvest brings an experienced team, a strong development pipeline and longstanding community relationships to TWC, further strengthening and expanding H2O America’s portfolio of locally led utilities and the company’s continued investment in essential infrastructure that delivers high-quality, reliable water services for more than 1.6 million people in four states.

“Our new colleagues bring deep knowledge of their systems and the communities that depend on them, and we join them in the ongoing responsibility Texas Water Company has to keep these water systems strong for decades to come,” said Aundrea Williams, president, TWC. With Quadvest now part of TWC, TWC will be able to draw on a broader pool of operational, engineering and technology expertise to support local teams, while preserving strong local leadership and accountability. “We look forward to building on Quadvest’s expertise and reputation that its leaders and teams have built, with customer relationships and dependable delivery of services people count on each day.”

While ownership of Quadvest’s assets has changed, operations continue without interruption for customers served by Quadvest systems. A passionate, dedicated team of locally based employees and leadership serving these Houston-area customers has been retained and will continue to serve these growing communities.

About Texas Water Company
The Texas Water Company has successfully provided high-quality and reliable water and wastewater service to Texas Hill Country customers since 2006. Quadvest has served Houston-area customers since 1978. Together now as Texas Water Company, we safeguard public health, promote environmental stewardship, and deliver sustainable solutions to the communities we serve – from management of water and wastewater treatment infrastructure, to the design and implementation of water reuse technology, water supply development and more. To learn more about our Hill Country operations, visit www.txwaterco.com. To learn more about our Quadvest operations, visit www.quadvest.com.

About H2O America
H2O America is among the largest investor-owned pure-play water and wastewater utilities in the United States, providing life-sustaining and high-quality water service to over 1.6 million people. H2O America’s locally led and operated water utilities – San Jose Water Company in California, The Connecticut Water Company in Connecticut, The Maine Water Company in Maine, and SJWTX, Inc. (dba The Texas Water Company) in Texas including Quadvest’s operations – possess the financial strength, operational expertise, and technological innovation to safeguard the environment, deliver outstanding service to customers, and provide opportunities to employees. H2O America remains focused on investing in its operations, remaining actively engaged in its local communities, and delivering continued sustainable value to its stockholders. For more information about H2O America, please visit www.h2o-america.com.

Forward Looking Statements
This release contains forward-looking statements within the meaning of the federal securities laws relating to future events and future results of H2O America and its subsidiaries that are based on current expectations, estimates, forecasts, and projections about H2O America and its subsidiaries and the industries in which H2O America and its subsidiaries operate and the beliefs and assumptions of the management of H2O America. Some of these forward-looking statements can be identified by the use of forward-looking words such as “believes,” “expects,” “projects,” “plans,” “estimates,” “anticipates,” “intends,” “seeks,” “plans,” “will,” “may,” “should,” “approximately,” “strategy,” or the negative of those words or other comparable terminology. These forward-looking statements are only predictions and are subject to risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed or forecasted in any forward-looking statements. The accuracy of such statements is subject to a number of risks, uncertainties and assumptions including, but not limited to, the following factors: (1) the ability to successfully integrate Quadvest’s operations and realize the projected financial and other benefits of the transaction, including the expectation that it will be accretive to H2O America’s long-term EPS growth rate; (2) the accuracy of projections regarding the anticipated growth in Texas; (3) the continued availability and performance of Quadvest’s and H2O America’s workforce and leadership teams during and after the transition; (4) the effect of water, utility, environmental and other governmental policies and regulations, including regulatory actions concerning rates, authorized return on equity, authorized capital structures, capital expenditures, per- and polyfluoroalkyl substances and other decisions; (5) changes in demand for water and other services; (6) catastrophic events such as fires, earthquakes, explosions, floods, ice storms, tornadoes, hurricanes, terrorist acts, physical attacks, cyber-attacks, epidemic, or similar occurrences; (7) unanticipated weather conditions and changes in seasonality including those affecting water supply and customer usage; (8) the effect of the impact of climate change; (9) unexpected costs, charges, expenses, delays or operational challenges in scaling infrastructure and expanding service; (10) our ability to successfully evaluate investments in new business and growth initiatives; (11) contamination of our water supplies and damage or failure of our water equipment and infrastructure; (12) the risk of work stoppages, strikes, and other labor-related actions; (13) changes and developments in general economic, political, legislative, business and financial market conditions; and (14) the ability to obtain financing on favorable terms, or at all, which can be affected by various factors, including credit ratings, changes in interest rates, compliance with regulatory requirements, compliance with the terms and conditions of our outstanding indebtedness, and general market and economic conditions.

The risks, uncertainties and other factors may cause the actual results, performance or achievements of H2O America to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

In addition, actual results are subject to these and other risks and uncertainties that relate more broadly to our overall business, including those more fully described in our filings with the SEC, including our most recent reports on Form 10-K, Form 10-Q and Form 8-K. Forward-looking statements are not guarantees of future performance, and speak only as of the date made, and H2O America undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

Texas Water Company Contact:
Brittany Pichler
Communications Supervisor
brittany.pichler@txwaterco.com

H2O America Contacts:

Media:
Michael Ambrozewicz
Vice President of Communications
Michael.Ambrozewicz@h2o-america.com

Investors:
Jonathan Reeder
Senior Director of Treasury and Investor Relations
Jonathan.Reeder@H2O-America.com

Ribbon cutting ceremony

Officially inauguration of Zealand Pharma Research Hub in Cambridge, MA.(From left: Eric Rojas, VP, Head of Investor Relations, Zealand Pharma; Yi-An Huang, Cambridge City Manager; Christina Sonnenborg Bredal, Chief People Officer, EVP, Zealand Pharma; Sumbul Siddiqui, Mayor of Cambridge; Jesper Møller Sørensen, Danish Ambassador to the United States; Adam Steensberg, CEO and President, Zealand Pharma; Martin Nicklasson, Chair of the Board, Zealand Pharma; Utpal Singh, Chief Scientific Officer, EVP, Zealand Pharma; Kendalle Burlin O’Connell, CEO and President, MassBio; David Maher, President and CEO, Cambridge Chamber of Commerce).
Officially inauguration of Zealand Pharma Research Hub in Cambridge, MA.(From left: Eric Rojas, VP, Head of Investor Relations, Zealand Pharma; Yi-An Huang, Cambridge City Manager; Christina Sonnenborg Bredal, Chief People Officer, EVP, Zealand Pharma; Sumbul Siddiqui, Mayor of Cambridge; Jesper Møller Sørensen, Danish Ambassador to the United States; Adam Steensberg, CEO and President, Zealand Pharma; Martin Nicklasson, Chair of the Board, Zealand Pharma; Utpal Singh, Chief Scientific Officer, EVP, Zealand Pharma; Kendalle Burlin O’Connell, CEO and President, MassBio; David Maher, President and CEO, Cambridge Chamber of Commerce).  

35 CambridgePark Drive

Exterior view.
Exterior view.

Press release – No. 19 / 2026

Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts 

  • Builds on the Metabolic Frontier 2030 strategy, advancing its ambition to become a leader in obesity and metabolic health
  • Ribbon-cutting ceremony marks the official opening of the Company’s primary U.S. address, expanding Zealand Pharma’s global research platform

Copenhagen, Denmark, and Boston, Massachusetts, September 30, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today celebrated the opening of its new research hub at 35 CambridgePark Drive in Cambridge, Massachusetts, with a ribbon-cutting ceremony. The site, first announced in March 2026, is now the primary U.S. address of Zealand Pharma.

The ceremony was led by Adam Steensberg, President and Chief Executive Officer of Zealand Pharma, alongside Utpal Singh, Executive Vice President and Chief Scientific Officer, Christina Sonnenborg Bredal, Chief People Officer, and Martin Nicklasson, Chair of the Board.

“Today, this research hub goes from vision to reality,” said Adam Steensberg, President and Chief Executive Officer of Zealand Pharma. “In December, we presented our ambition to become a leader in obesity and metabolic health. This research hub is a commitment to achieve that ambition. Tomorrow, our scientists begin research here, joining colleagues in Copenhagen, and I am excited to see this long-term investment and bridging between two leading life science communities flourish.”

“The Cambridge hub will expand our platform and the biology we can modulate ” said Utpal Singh, Executive Vice President and Chief Scientific Officer of Zealand Pharma. “This is integral to becoming a Generational Biotech. With automation and advanced modeling methodologies complemented with human intuition as the foundation of how we work here, we expect to move faster from idea to clinic, and Cambridge puts us shoulder to shoulder with some of the best scientific talent in the world to help us do it.”

Expanding Zealand Pharma’s Research Platform

The 53,600 RSF (approximately 5,000 m2) Cambridge site expands Zealand Pharma’s research capabilities beyond its core peptide expertise into hybrid modalities, including biologics such as antibody peptide conjugates. The platform will be built around automation and advanced modeling techniques to shorten the cycle time from idea to clinic.  

Joining Cambridge’s Life Sciences Community

Cambridge is home to more than 600 life sciences companies and some of the world’s leading academic and research talent. Zealand Pharma is actively hiring at the site, with continued growth expected, and has joined the Cambridge Chamber of Commerce as a new contributor to the Massachusetts life sciences economy.


Ribbon Cutting Ceremony to officially inaugurate Zealand Pharma Research Hub in Cambridge, MA.
(From left: Eric Rojas, VP, Head of Investor Relations, Zealand Pharma; Yi-An Huang, Cambridge City Manager; Christina Sonnenborg Bredal, Chief People Officer, EVP, Zealand Pharma; Sumbul Siddiqui, Mayor of Cambridge; Jesper Møller Sørensen, Danish Ambassador to the United States; Adam Steensberg, CEO and President, Zealand Pharma; Martin Nicklasson, Chair of the Board, Zealand Pharma; Utpal Singh, Chief Scientific Officer, EVP, Zealand Pharma; Kendalle Burlin O’Connell, CEO and President, MassBio; David Maher, President and CEO, Cambridge Chamber of Commerce).  


35 CambridgePark Drive in Cambridge, Massachusetts.

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data-driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health.

To date, more than ten Zealand Pharma-invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization.

Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Cambridge, Massachusetts. Learn more at www.zealandpharma.com.

Forward looking statements 
This press release contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Pharma’s expectations or forecasts of future events regarding the research, development and commercialization of pharmaceutical products, the timing of the company’s pre-clinical and clinical trials and the reporting of data therefrom. These forward-looking statements may be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,” “would” and other words and terms of similar meaning. You should not place undue reliance on these statements, or the scientific data presented. The reader is cautioned not to rely on these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect, and which include, but are not limited to, unexpected costs or delays in clinical trials and other development activities due to adverse safety events, patient recruitment or otherwise; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; our ability to successfully market both new and existing products; changes in reimbursement rules and governmental laws and related interpretation thereof; government-mandated or market-driven price decreases for our products; introduction of competing products; production problems at third party manufacturers; dependency on third parties, for instance contract research or development organizations; unexpected growth in costs and expenses; our ability to affect the strategic reorganization of our businesses in the manner planned; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; regulatory authorities may require additional information or further studies, or may reject, fail to approve or may delay approval of our drug candidates or expansion of product labeling; failure to obtain regulatory approvals in other jurisdictions; exposure to product liability and other claims; interest rate and currency exchange rate fluctuations; unexpected contract breaches or terminations; inflationary pressures on the global economy; and political uncertainty. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. All such forward-looking statements speak only as of the date of this company announcement and are based on information available to Zealand Pharma as of the date of this announcement. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.

Zealand Pharma® is a registered trademark of Zealand Pharma A/S.

Contacts
Eric Rojas (Investors)
Vice President, Head of Investor Relations
erojas@zealandpharma.com

Neshat Anis Ahmadi (Investors)
Investor Relations Manager
neahmadi@zealandpharma.com

Rachel James-Owens (Media)
Vice President, Corporate Communications and Media Relations
rjamesowens@zealandpharma.com

Andreas Hylleberg (Media)
Director, External Communications
ahylleberg@zealandpharma.com

Amber Fennell, Jessica Hodgson, and Sean Leous (Media)
ICR Healthcare
ZealandPharma@icrhealthcare.com
+44 (0) 7739 658 783

Attachments

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.